The test will work on the existing Truenat machines that are deployed across over 3500 PHCs/CHCs and over 1200 private labs and hospitals across India, making it possible for patients to obtain a quick diagnosis at all levels of the healthcare chain
Molbio Diagnostics has launched the Truenat H3N2/H1N1 for differential diagnosis of the H3N2 and H1N1 virus. The test is approved by the Central Drugs Standard Control Organization (CDSCO) and can provide sample-to-result in an hour’s time. Truenat H3N2/H1N1 is the first point-of-care Real-Time PCR test that aids in the confirmatory diagnosis of Influenza infections. The test will work on the existing Truenat machines that are deployed across over 3500 PHCs/CHCs and over 1200 private labs and hospitals across India, making it possible for patients to obtain a quick diagnosis at all levels of the healthcare chain.
India is currently seeing a surge in influenza viral infections due to H3N2 and H1N1. The viruses that spread through the air, have the ability for sustained human-to-human transmission, which can potentially cause an influenza pandemic. Therefore it is of utmost importance to have an early confirmatory diagnosis to initiate rapid disease management efforts for controlling the spread and reducing influenza-related morbidity and mortality, both during seasonal epidemics and pandemics.
Commenting on the launch, Sriram Natarajan, CEO, Founder, and Director, of Molbio Diagnostics, said, “The launch of Truenat H3N2/H1N1 further strengthens Molbio’s product portfolio by providing complete testing solutions for respiratory illnesses. The multi-disease testing capability of the Truenat platform keeps health care facilities prepared to combat all kinds of pandemics and disease outbreaks at early stage. Going forward, Molbio will continue to bring innovative solutions for better patient management and appropriate treatment of the disease.”
Also commenting on the launch, Dr Chandrasekhar Nair, CTO, and Director, of Molbio Diagnostics, said, “It is imperative that molecular methods such as Polymerase Chain Reaction (PCR) or Real-Time PCR are used to revolutionize disease diagnosis and management. Truenat has been a game changer in this regard as a point-of-care molecular platform that offers more than 40 tests right at the point of need. The launch of the Truenat H3N2/H1N1 test is just another milestone in our respiratory diseases portfolio.”
Molecular methods such as Polymerase Chain Reaction (PCR) or Real-Time PCR are revolutionising disease diagnosis and management. Truenat, a point-of-care, portable, battery-operated, IoT-enabled, multi-disease, Real-Time PCR platform, has been a game changer in this regard. Truenat offers tests for over 40 diseases such as COVID-19, TB, HCV, HBV, HIV, HPV, Dengue, Malaria, Influenza, Nipah and typhoid right at the point of need.
- Advertisement -